Mailed HIV Self-Tests Can Improve Access to Testing in Priority Audiences

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, June 20, 2024 -- Mailed HIV-self tests (HIVSTs) can increase testing among persons who have never received testing for HIV or have not received testing in the past year, according to research published in the June 20 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Travis Sanchez, from Emory University in Atlanta, and colleagues examined use of HIVSTs, which were publicized by the CDC to priority audiences, particularly those disproportionately affected by HIV. The online ordering portal was launched March 14, 2023, to expand distribution of HIVSTs directly to consumers.

Through March 13, 2024, 443,813 tests were distributed to 219,360 persons. The researchers found that of the 169,623 persons who answered at least one question on a postorder questionnaire, 67.9 percent were from priority audiences, and 24.1 and 24.8 percent had never previously received HIV testing and had not received testing in the past year, respectively. Among those who initiated a follow-up survey, 88.3, 27.1, 11.7, and 1.9 percent used an HIVST themselves, gave away an HIVST, accessed additional preventive services, and reported a new positive HIVST result, respectively.

"Clinicians, community organizations, and public health officials need to be aware of HIVST programs, initiate discussions about HIV testing conducted outside their clinics or offices, and initiate follow-up services for persons who report a positive or negative HIVST result," the authors write.

One author disclosed ties to OraSure Technologies for related work; a second author disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords